A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.

A medicament characterized in that (A) a compound represented by the formula (I):

##STR00001##

its pharmaceutically acceptable salt, or a solvate thereof,
wherein
P is hydrogen or a group to form a prodrug;
A.sup.1 is CR.sup.1AR.sup.1B, S or O;
A.sup.2 is CR.sup.2AR.sup.2B, S or O;
A.sup.3 is CR.sup.3AR.sup.3B, S or O;
A.sup.4 is each independently CR.sup.4AR.sup.4B, S or O;
the number of hetero atoms among atoms constituting the ring which consists of A.sup.1, A.sup.2, A.sup.3, A.sup.4, nitrogen atom adjacent to A.sup.1 and carbon atom adjacent to A.sup.4 is 1 or 2;
R.sup.1A and R.sup.1B are each independently hydrogen, halogen, alkyl or the like;
R.sup.2A and R.sup.2B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.3A and R.sup.3B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.4A are each independently hydrogen, halogen, alkyl, or the like;
R.sup.4B are each independently hydrogen, halogen, alkyl, or the like;
R.sup.3A and R.sup.3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle;
n is any integer of 1 to 2; and
R.sup.1 is

##STR00002##

or the like,
is combined with (B) compound(s) having an anti-influenza activity, its pharmaceutically acceptable salt or a solvate thereof and/or an antibody having anti-influenza activity, is useful for treating or preventing influenza.

In one aspect, a method of treating smokeless tobacco addiction comprising administering to an individual in need thereof a pharmaceutical composition comprising nicotine, a therapeutically effective amount of cannabidiol, and a pharmaceutically acceptable vehicle therefor. In some aspects, the composition is administered transmucosally, such as in an oral dosage form or nasal spray. In other aspects, the composition is administered transdermally. In another aspect, a chewable gum contains nicotine in at least a base portion and cannabidiol in at least an outer portion thereof.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

An electrically stimulated CBD infused anesthetic patch system that is placed on a human's skin that is used to relieve pain. The electrically stimulated CBD infused anesthetic patch system comprises of a transdermal patch that has electrodes that receive an electric current from a TENS device. The transdermal patch is impregnated with a solution that has at least one analgesic that is selected from the group consisting of Menthol, CBD, Lidocaine or Capsaicin. The solution shall also include inactive ingredients.

A transdermal formulation which can be applied to the skin, body, face using a combination of glutathione, in the presence of a wide range of active components while increasing permeation of active antioxidant agents. A therapeutically effective amount creates in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.

In one aspect, a method of treating smokeless tobacco addiction comprising administering to an individual in need thereof a pharmaceutical composition comprising nicotine, a therapeutically effective amount of cannabidiol, and a pharmaceutically acceptable vehicle therefor. In some aspects, the composition is administered transmucosally, such as in an oral dosage form or nasal spray. In other aspects, the composition is administered transdermally. In another aspect, a chewable gum contains nicotine in at least a base portion and cannabidiol in at least an outer portion thereof.

A method of treating cough includes applying a therapeutic foot patch to a bottom of a foot. The therapeutic foot patch has a flexible backing with a skin contact side that contacts the bottom of the foot. An active ingredient carrier section on the skin contact side carries a cough-reducing active ingredient that imparts a chemesthetic sensation to the foot.

The present invention relates to aransdermal therapeutic system for the transdermal administration of a systemically active agent having a self-adhesive layer structure. The transdermal therapeutic system includes (A) a backing layer, and (B) a dried biphasic layer. The dried biphasic layer has (a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and (b) an inner phase having a composition that includes at least one active agent. The inner phase forms dispersed deposits in the outer phase, with the dried biphasic layer including (c) from 0.1% to 3.5% of an interface mediator other than silicone oil, with the interface mediator having with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25 C.